Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

Open Access 01-02-2020 | Schizophrenia | Editorial

Therapy resistance/chronicity, their determinants and potential solutions

Author: Hans-Jürgen Möller

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 1/2020

Excerpt

The current volume is indeed directed to clinicians and their everyday clinical work. It covers several psychopharmacological issues of great clinical relevance: therapy resistance, chronicity, side effects. All three of them belong to the general topic of difficult-to-treat patients. In this editorial, I will focus on those papers which focus on therapy resistance/chronicity. …

Rickels K et al (2019) Benzodiazepines in anxiety disorders: reassessment of usefulness and safety. World J Biol Psychiatry 20(7):514–518CrossRef

Seemüller F et al (2010) Outcomes of 1014 naturalistically treated inpatients with major depressive disorder. Eur Neuropsychopharmacol 20(5):346–355CrossRef

Seemüller F et al (2014) Three-year long-term outcome of 458 naturalistically treated inpatients ith major depressive episode: severe relapse rates and risk factors. Eur Arch Psychiatry Clin Neurosci 264(5):67–575

Schennach R et al (2015) What are residual symptoms in schizophrenia spectrum disorders? Clinical description and 1-year persistence within a naturalistic trial. Eur Arch Psychiatry Clin Neurosci 265:107–116CrossRef

Möller HJ et al (2016) The relevance of “mixed anxiety and depression” as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci 266(8):725–736CrossRef

Riedel M et al (2005) Risperidone plasma levels, clinical response and side effects. Eur Arch Psychiatry Clin Neurosci 255:261–268CrossRef

Möller HJ et al (2015) Pharmacological treatment of negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 265(7):567–578CrossRef

Title: Therapy resistance/chronicity, their determinants and potential solutions
Author: Hans-Jürgen Möller
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Keywords: Schizophrenia
Mood Disorders
Antipsychotics
Affective Disorder
Esketamine
Antipsychotics
Clozapine
Benzodiazepine
Esketamin
Ketamine
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 1/2020
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-020-01101-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Therapy resistance/chronicity, their determinants and potential solutions

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design

Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study

Mental health in refugees and asylum seekers (MEHIRA): study design and methodology of a prospective multicentre randomized controlled trail investigating the effects of a stepped and collaborative care model

Inhibition of monoamine oxidase activity by repetitive transcranial magnetic stimulation: implications for inter-train interval and frequency

Severe parkinsonism under treatment with antipsychotic drugs

Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015